FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2416031804> ?p ?o ?g. }

• W2416031804 endingPage "57" @default.
• W2416031804 startingPage "54" @default.
• W2416031804 abstract "1. George A. Fritsma, MS MT (ASCP)[⇑][1] 1. The Fritsma Factor, Your Interactive Hemostasis ResourceSM, Fritsma & Fritsma LLC, Birmingham, AL 1. Address for Correspondence: George A. Fritsma MS MT (ASCP), The Fritsma Factor, Your Interactive Hemostasis ResourceSM, Fritsma & Fritsma LLC, 153 Redwood Drive, Birmingham, AL 357173, 205-655-0687, George{at}fritsmafactor.com. 1. Diagram the physiology of the direct thrombin inhibitors2. Distinguishe between argatroban and bivalirudin.3. Provide the means for monitoring direct thrombin inhibitors.The direct thrombin inhibitors (DTIs), intravenous argatroban and bivalirudin and oral dabigatran, reversibly bind and inactivate free and clot-bound thrombin without activating antithrombin (AT, antithrombin III, ATIII), thereby suppressing coagulation at the final stage of the cascade.1 Argatroban or bivalirudin are substituted for unfractionated heparin (UFH) or low molecular weight heparin (LMWH) when heparin-induced thrombocytopenia with thrombosis (HIT) is suspected or confirmed, as they do not interact with the HIT antibody.2 When HIT is suspected, the risk of either venous or arterial thrombosis is 50% for 30 days after heparin withdrawal unless argatroban or bivalirudin is employed. Coumadin is contraindicated in HIT as it is prothrombotic for the first 5 days of administration. Dabigatran has been cleared for prevention of venous thromboembolic (VTE) disease in Europe and Canada and for prevention of stroke in atrial fibrillation in the US. As the first new oral anticoagulant cleared by the FDA since 1954, dabigatran is beginning to take its place in the formulary. Laboratory scientists are challenged to find clinically effective means to monitor its plasma concentration.Argatroban Argatroban (Novostan®; GlaxoSmithKline, Research Triangle Park, NC) is a non-protein l-arginine derivative with a molecular weight of 527 Daltons.3 Argatroban was FDA-cleared in 1997 for anticoagulation in HIT.4 Argatroban may be used for prophylaxis, treatment, and also for anticoagulation during percutaneous cardiac intervention (PCI, cardiac catheterization) for patients with HIT.5The physician initiates the argatroban intravenous infusion at 2 μg/kg/min or in patients with liver disease at 0.5 μg/kg/min. During PCI, a bolus of…ABBREVIATIONS: APTT or PTT - activated partial thromboplastin time; AT - antithrombin; CAD – coronary artery disease; DTI - direct thrombin inhibitor; DVT - deep venous thrombosis; ECT-ecarin clotting time; FDA - US Food and Drug Administration; HIT - heparin-induced thrombocytopenia with thrombosis; INR - international normalized ratio; LMWH - low molecular weight heparin; PE - pulmonary embolism; PCI - percutaneous intervention (cardiac catheterization); PiCT - prothrombinase-induced clotting time; PT - prothrombin time; RI - reference interval; RUO - research use only; TCT - thrombin clotting time; TPA - tissue plasminogen activator; UFH - unfractionated heparin; VTE - venous thromboembolism.1. Diagram the physiology of the direct thrombin inhibitors2. Distinguishe between argatroban and bivalirudin.3. Provide the means for monitoring direct thrombin inhibitors. [1]: #corresp-1" @default.
• W2416031804 created "2016-06-24" @default.
• W2416031804 creator A5000160412 @default.
• W2416031804 date "2013-01-01" @default.
• W2416031804 modified "2023-10-16" @default.
• W2416031804 title "Monitoring the Direct Thrombin Inhibitors" @default.
• W2416031804 doi "https://doi.org/10.29074/ascls.26.1.54" @default.
• W2416031804 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23479838" @default.
• W2416031804 hasPublicationYear "2013" @default.
• W2416031804 type Work @default.
• W2416031804 sameAs 2416031804 @default.
• W2416031804 citedByCount "2" @default.
• W2416031804 countsByYear W24160318042015 @default.
• W2416031804 countsByYear W24160318042022 @default.
• W2416031804 crossrefType "journal-article" @default.
• W2416031804 hasAuthorship W2416031804A5000160412 @default.
• W2416031804 hasBestOaLocation W24160318041 @default.
• W2416031804 hasConcept C126322002 @default.
• W2416031804 hasConcept C177713679 @default.
• W2416031804 hasConcept C2777292125 @default.
• W2416031804 hasConcept C3018972837 @default.
• W2416031804 hasConcept C57002609 @default.
• W2416031804 hasConcept C71924100 @default.
• W2416031804 hasConcept C89560881 @default.
• W2416031804 hasConceptScore W2416031804C126322002 @default.
• W2416031804 hasConceptScore W2416031804C177713679 @default.
• W2416031804 hasConceptScore W2416031804C2777292125 @default.
• W2416031804 hasConceptScore W2416031804C3018972837 @default.
• W2416031804 hasConceptScore W2416031804C57002609 @default.
• W2416031804 hasConceptScore W2416031804C71924100 @default.
• W2416031804 hasConceptScore W2416031804C89560881 @default.
• W2416031804 hasIssue "1" @default.
• W2416031804 hasLocation W24160318041 @default.
• W2416031804 hasLocation W24160318042 @default.
• W2416031804 hasOpenAccess W2416031804 @default.
• W2416031804 hasPrimaryLocation W24160318041 @default.
• W2416031804 hasRelatedWork W1963913381 @default.
• W2416031804 hasRelatedWork W1979033915 @default.
• W2416031804 hasRelatedWork W2023338794 @default.
• W2416031804 hasRelatedWork W2045201221 @default.
• W2416031804 hasRelatedWork W2075965017 @default.
• W2416031804 hasRelatedWork W2114467497 @default.
• W2416031804 hasRelatedWork W2312656935 @default.
• W2416031804 hasRelatedWork W2377642878 @default.
• W2416031804 hasRelatedWork W2402244052 @default.
• W2416031804 hasRelatedWork W2914662581 @default.
• W2416031804 hasVolume "26" @default.
• W2416031804 isParatext "false" @default.
• W2416031804 isRetracted "false" @default.
• W2416031804 magId "2416031804" @default.
• W2416031804 workType "article" @default.